Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in treatments for rare and ultrarare genetic diseases, has announced a conference call scheduled for November 5, 2024, at 5:00 p.m. ET. The call will discuss the company's third quarter 2024 financial results and provide a corporate update for the period ending September 30, 2024. The event will be accessible via webcast through the company's investor relations website, with a replay available for three months.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una azienda biofarmaceutica specializzata nel trattamento delle malattie genetiche rare e ultrarerare, ha annunciato una conference call prevista per il 5 novembre 2024, alle 17:00 ET. Durante la chiamata verranno discussi i risultati finanziari del terzo trimestre 2024 e fornito un aggiornamento aziendale per il periodo che si conclude il 30 settembre 2024. L'evento sarà accessibile tramite webcast sul sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile per tre mesi.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una compañía biofarmacéutica especializada en tratamientos para enfermedades genéticas raras y ultrararas, ha anunciado una conferencia telefónica programada para el 5 de noviembre de 2024, a las 5:00 p.m. ET. La llamada discutirá los resultados financieros del tercer trimestre de 2024 y proporcionará una actualización corporativa para el período que finaliza el 30 de septiembre de 2024. El evento será accesible a través de un webcast en el sitio web de relaciones con inversores de la compañía, con una repetición disponible durante tres meses.
Ultragenyx Pharmaceutical (NASDAQ: RARE), 드문 유전 질환 및 초희귀 유전 질환 치료에 특화된 생명공학 회사가 2024년 11월 5일 오후 5시(동부 표준시)에 예정된 컨퍼런스 콜을 발표했습니다. 이 콜에서는 2024년 3분기 재무 결과와 2024년 9월 30일에 종료되는 기간에 대한 기업 업데이트가 논의될 예정입니다. 이 이벤트는 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 접근할 수 있으며, 3개월 동안 재청취가 가능합니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE), une entreprise biopharmaceutique spécialisée dans le traitement des maladies génétiques rares et ultraraires, a annoncé une conférence téléphonique prévue pour le 5 novembre 2024 à 17h00 ET. L'appel discutera des résultats financiers du troisième trimestre 2024 et fournira une mise à jour de l'entreprise pour la période se terminant le 30 septembre 2024. L'événement sera accessible par webinaire via le site de relations investisseurs de l'entreprise, avec un replay disponible pendant trois mois.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung seltener und ultrarara genetischer Erkrankungen spezialisiert hat, hat eine Telefonkonferenz für den 5. November 2024 um 17:00 Uhr ET angekündigt. In dem Gespräch werden die Finanzergebnisse des dritten Quartals 2024 besprochen und ein Unternehmensupdate für den Zeitraum bis zum 30. September 2024 gegeben. Die Veranstaltung wird über einen Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiederholung, die drei Monate verfügbar ist.
- None.
- None.
NOVATO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 5, 2024, to discuss its financial results and corporate update for the quarter ending September 30, 2024.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
(415) 475-6370
Media
Joey Fleury
(707) 368-5020
FAQ
When is Ultragenyx (RARE) hosting its Q3 2024 earnings call?
How can investors access Ultragenyx's (RARE) Q3 2024 earnings call?
How long will the replay of Ultragenyx's (RARE) Q3 2024 earnings call be available?
